Search research articles
Contact Us
Filters
Showing results (271-280 of 418) with videos related to
Page
of 42
Sort By:
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Cancer Cell
|
January 21, 2015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction
Gatien Moriceau, Willy Hugo, Aayoung Hong, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The Oncologist
|
December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
James Larkin, Mototsugu Oya, Marcella Martignoni, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
James Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
The Lancet. Oncology
|
June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V Long, Reinhard Dummer, Omid Hamid, et al.
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A Ascierto, Brigitte Dréno, James Larkin, et al.
Page
of 42
Search research articles
Search
Showing results (271-280 of 418) with videos related to
Sort By:
Page
of 42
The Lancet. Oncology
|
February 3, 2020
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF<sup>V600</sup>-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer, Jan C Brase, James Garrett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 22, 2023
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
Caroline Robert, Matteo S Carlino, Catriona McNeil, et al.
Cancer Cell
|
January 21, 2015
Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction
Gatien Moriceau, Willy Hugo, Aayoung Hong, et al.
Lancet (London, England)
|
August 21, 2017
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V Long, et al.
The Oncologist
|
December 28, 2022
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
James Larkin, Mototsugu Oya, Marcella Martignoni, et al.
The New England Journal of Medicine
|
September 30, 2014
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma
James Larkin, Paolo A Ascierto, Brigitte Dréno, et al.
The Lancet. Oncology
|
June 22, 2019
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina V Long, Reinhard Dummer, Omid Hamid, et al.
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
The New England Journal of Medicine
|
September 3, 2020
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer, Axel Hauschild, Mario Santinami, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 23, 2021
5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study
Paolo A Ascierto, Brigitte Dréno, James Larkin, et al.
Page
of 42